NCT05178901View on ClinicalTrials.gov

A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Nipah Virus Infection
Interventions
BIOLOGICAL

PHV02

live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection

OTHER

Placebo

Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection

Trial Locations (1)

66219

Johnson County Clin-Trials(JCCT), Lenexa

All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Public Health Vaccines LLC

INDUSTRY

NCT05178901 - A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter